Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ERNA Ernexa Therapeutics	$1.85 -2.6%	$2.91	$1.75 ▼ $39.38	$13.99M	5.55	197,734 shs	8,338 shs
NRXP NRx Pharmaceuticals	$3.42 -2.3%	$2.67	$1.10 ▼ $6.01	$60.51M	1.54	418,033 shs	258,499 shs
SNTI Senti Biosciences	$2.16 +2.4%	$3.15	$1.52 ▼ $16.94	$55.03M	2.23	812,548 shs	89,226 shs
VRCA Verrica Pharmaceuticals	$0.52 -10.3%	$0.55	$0.38 ▼ $8.98	$53.88M	1.75	601,452 shs	3.89 million shs

Reduce the Risk

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ERNA Ernexa Therapeutics	-2.63%	-24.49%	-46.38%	-29.28%	-93.07%
NRXP NRx Pharmaceuticals	-2.29%	+4.91%	+32.05%	+68.47%	+41.91%
SNTI Senti Biosciences	+2.37%	+1.41%	-32.71%	-37.03%	-29.71%
VRCA Verrica Pharmaceuticals	-10.28%	-10.64%	-3.19%	+20.69%	-92.59%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ERNA Ernexa Therapeutics	0.9358 of 5 stars	0.0	5.0	0.0	1.8	1.7	0.0
NRXP NRx Pharmaceuticals	1.9731 of 5 stars	3.6	1.0	0.0	2.5	0.8	0.6
SNTI Senti Biosciences	2.6954 of 5 stars	3.5	3.0	0.0	2.8	0.0	1.3
VRCA Verrica Pharmaceuticals	4.0644 of 5 stars	3.1	1.0	4.7	3.3	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ERNA Ernexa Therapeutics	0.00	N/A	N/A	N/A
NRXP NRx Pharmaceuticals	3.20	Buy	$28.50	733.33% Upside
SNTI Senti Biosciences	3.00	Buy	$8.50	293.52% Upside
VRCA Verrica Pharmaceuticals	2.20	Hold	$8.00	1,430.81% Upside

Current Analyst Ratings Breakdown

Latest ERNA, SNTI, VRCA, and NRXP Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/20/2025	NRXP NRx Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$31.00
6/12/2025	SNTI Senti Biosciences	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$12.00
6/6/2025	NRXP NRx Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$31.00
6/6/2025	SNTI Senti Biosciences	Laidlaw Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$5.00
5/16/2025	NRXP NRx Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$31.00 ➝ $31.00
5/14/2025	VRCA Verrica Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
5/2/2025	SNTI Senti Biosciences	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$12.00 ➝ $12.00
4/30/2025	NRXP NRx Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$31.00 ➝ $31.00
4/29/2025	NRXP NRx Pharmaceuticals	Ascendiant Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$45.00 ➝ $46.00
4/9/2025	VRCA Verrica Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
4/8/2025	VRCA Verrica Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral

(Data available from 6/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ERNA Ernexa Therapeutics	$580K	23.48	N/A	N/A	$0.50 per share	3.70
NRXP NRx Pharmaceuticals	N/A	N/A	N/A	N/A	($1.48) per share	N/A
SNTI Senti Biosciences	$2.56M	22.01	N/A	N/A	$5.31 per share	0.41
VRCA Verrica Pharmaceuticals	$7.57M	6.39	N/A	N/A	($0.11) per share	-4.75

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ERNA Ernexa Therapeutics	-$44.54M	-$8.31	N/A	∞	N/A	-7,652.75%	N/A	-285.71%	8/11/2025 (Estimated)
NRXP NRx Pharmaceuticals	-$25.13M	-$2.01	N/A	N/A	N/A	N/A	N/A	-355.00%	8/13/2025 (Estimated)
SNTI Senti Biosciences	-$52.79M	-$10.84	N/A	N/A	N/A	N/A	-177.24%	-67.38%	8/12/2025 (Estimated)
VRCA Verrica Pharmaceuticals	-$76.58M	-$1.20	N/A	N/A	N/A	N/A	N/A	-145.63%	8/13/2025 (Estimated)

Latest ERNA, SNTI, VRCA, and NRXP Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q1 2025	NRXP NRx Pharmaceuticals	-$0.40	-$0.34	+$0.06	-$0.34	$1.14 million	$1.14 million
5/13/2025	Q1 2025	VRCA Verrica Pharmaceuticals	-$0.14	-$0.10	+$0.04	-$0.10	$2.53 million	$3.44 million
5/6/2025	Q1 2025	SNTI Senti Biosciences	-$0.56	-$1.41	-$0.85	-$1.41	$1.30 million	$1.30 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ERNA Ernexa Therapeutics	N/A	N/A	N/A	N/A	N/A
NRXP NRx Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
SNTI Senti Biosciences	N/A	N/A	N/A	N/A	N/A
VRCA Verrica Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ERNA Ernexa Therapeutics	N/A	0.21	0.21
NRXP NRx Pharmaceuticals	N/A	0.22	0.22
SNTI Senti Biosciences	N/A	4.22	4.22
VRCA Verrica Pharmaceuticals	N/A	1.34	1.26

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ERNA Ernexa Therapeutics	70.55%
NRXP NRx Pharmaceuticals	4.27%
SNTI Senti Biosciences	25.73%
VRCA Verrica Pharmaceuticals	42.45%

Insider Ownership

Company	Insider Ownership
ERNA Ernexa Therapeutics	1.50%
NRXP NRx Pharmaceuticals	19.00%
SNTI Senti Biosciences	3.12%
VRCA Verrica Pharmaceuticals	54.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ERNA Ernexa Therapeutics	10	7.36 million	7.26 million	No Data
NRXP NRx Pharmaceuticals	2	17.29 million	14.00 million	Optionable
SNTI Senti Biosciences	4	26.08 million	25.27 million	Not Optionable
VRCA Verrica Pharmaceuticals	40	92.49 million	42.55 million	Optionable

ERNA, SNTI, VRCA, and NRXP Headlines

Recent News About These Companies

Verrica Shareholder Sues Board Over FDA Approval Hurdle Claims

June 27 at 7:35 PM | news.bloomberglaw.comN

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Short Interest Update

June 19, 2025 | americanbankingnews.com

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Receives $8.00 Consensus PT from Analysts

June 19, 2025 | americanbankingnews.com

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Sees Significant Decline in Short Interest

June 18, 2025 | marketbeat.com

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Given Average Recommendation of "Hold" by Brokerages

June 16, 2025 | marketbeat.com

Verrica Pharmaceuticals (NASDAQ:VRCA) Shares Up 0% - Here's Why

June 10, 2025 | marketbeat.com

Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in New York

May 28, 2025 | globenewswire.com

Verrica Pharmaceuticals Reports Record Q1 Revenue and Advancements in Pipeline

May 18, 2025 | msn.com

Verrica Pharmaceuticals, Inc. (VRCA) Q1 2025 Corporate Update Conference Call

May 13, 2025 | seekingalpha.com

Verrica Pharmaceuticals Inc. (VRCA) Reports Q1 Loss, Tops Revenue Estimates

May 13, 2025 | zacks.com

Verrica Pharmaceuticals Reports Quarterly 2025 Financial Results

May 13, 2025 | globenewswire.com

6VRCA : Earnings Outlook For Verrica Pharmaceuticals

May 13, 2025 | benzinga.com

Verrica Pharmaceuticals to Host Q1 2025 Earnings Call and Corporate Update

May 11, 2025 | msn.com

Verrica Pharmaceuticals to Report First Quarter 2025 Financial Results and Provide a Corporate Update on May 13, 2025

May 7, 2025 | globenewswire.com

Verrica Pharmaceuticals CEO to Present at Citizens Life Sciences Conference

May 4, 2025 | msn.com

Verrica Pharmaceuticals to Participate in the Citizens Life Sciences Conference in New York

April 30, 2025 | globenewswire.com

Why Verrica Pharmaceuticals Inc.’s (VRCA) Stock Is Down 5.94%

April 9, 2025 | aaii.comA

Verrica Pharmaceuticals Reports Strong First-Quarter Growth for YCANTH

April 9, 2025 | msn.com

In face of U.S. stock market selloff, shares of West Chester firm are on the rise

April 8, 2025 | bizjournals.com

Verrica Pharmaceuticals experiences ‘strong demand-led growth’ for YCANTH in Q1

April 8, 2025 | markets.businessinsider.com

Verrica Pharmaceuticals Reports Strong Demand-Led Growth in YCANTH® Dispensed Applicator Units in First Quarter 2025

April 7, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

3 Catalysts in 7 Days: Archer's Growth Story Just Accelerated
By Jeffrey Neal Johnson | June 18, 2025
View 3 Catalysts in 7 Days: Archer's Growth Story Just Accelerated
3 AI Infrastructure Stocks With Strong Growth, Not Hype
By Chris Markoch | June 26, 2025
View 3 AI Infrastructure Stocks With Strong Growth, Not Hype
Top 3 Silver Picks to Watch as Bull Market Gains Steam
By Chris Markoch | June 18, 2025
View Top 3 Silver Picks to Watch as Bull Market Gains Steam
These 3 Stocks Are Buying Back Billions in Shares
By Leo Miller | June 3, 2025
View These 3 Stocks Are Buying Back Billions in Shares
D-Wave Goes International With South Korea Partnership
By Nathan Reiff | June 23, 2025
View D-Wave Goes International With South Korea Partnership

ERNA, SNTI, VRCA, and NRXP Company Descriptions

Ernexa Therapeutics NASDAQ:ERNA

$1.85 -0.05 (-2.63%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$1.86 +0.01 (+0.81%)

As of 06/27/2025 06:27 PM Eastern

Eterna Therapeutics Inc., a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.

NRx Pharmaceuticals NASDAQ:NRXP

$3.42 -0.08 (-2.29%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$3.46 +0.04 (+1.14%)

As of 06/27/2025 07:53 PM Eastern

NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior. The company has a partnership with Alvogen Inc. and Lotus Pharmaceutical Company; development and manufacturing agreement with Nephron Pharmaceuticals, Inc. and Alcami; license agreement with Apkarian Technologies; development and license agreement with Glytech; license agreement with Sarah Herzog Memorial Hospital. The company was founded in 2015 and is based in Wilmington, Delaware.

Senti Biosciences NASDAQ:SNTI

$2.16 +0.05 (+2.37%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$2.07 -0.09 (-4.21%)

As of 06/27/2025 07:45 PM Eastern

Senti Biosciences, Inc. operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma. It also develops SENTI-401, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate colorectal cancer/CRC cells. In addition, the company develops Tumor-Associated Antigen and Protective Antigen Paired Discovery Platform to select and validate NOT GATE antigen candidates and identify tumor-associated antigens in cancer cells. The company has a strategic collaboration with Celest Therapeutics (Shanghai) Co. Ltd for the clinical development of SENTI-301A to treat solid tumors. Senti Biosciences, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

Verrica Pharmaceuticals NASDAQ:VRCA

$0.52 -0.06 (-10.28%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$0.57 +0.05 (+8.88%)

As of 06/27/2025 05:50 PM Eastern

Verrica Pharmaceuticals Inc., a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts. The company also develops VP-315, an oncolytic peptide-based injectable therapy, which is in phase II clinical trial for the treatment of dermatology oncologic conditions which includes basal cell carcinoma; and VP-103, a cantharidin-based product candidate for the treatment of plantar warts and is in phase II clinical trial. In addition, it offers YCANTH for the treatment of molluscum contagiosum. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for dermatological oncology indications, such as non-metastatic melanoma and non-metastatic merkel cell carcinoma. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time